
Global Injectable HIV Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031
Description
Summary
According to APO Research, The global Injectable HIV Treatment market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Injectable HIV Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Injectable HIV Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Injectable HIV Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Injectable HIV Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Injectable HIV Treatment include Theratechnologies, ViiV Healthcare, Gilead Sciences and Janssen Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Injectable HIV Treatment, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Injectable HIV Treatment, also provides the sales of main regions and countries. Of the upcoming market potential for Injectable HIV Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Injectable HIV Treatment sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Injectable HIV Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Injectable HIV Treatment sales, projected growth trends, production technology, application and end-user industry.
Injectable HIV Treatment Segment by Company
Theratechnologies
ViiV Healthcare
Gilead Sciences
Janssen Pharmaceuticals
Injectable HIV Treatment Segment by Type
Cabotegravir
Lenacapavir
Rilpivirine
Ibalizumab
Other
Injectable HIV Treatment Segment by Application
Pre-Exposure Prophylaxis
HIV Treatment
Injectable HIV Treatment Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Injectable HIV Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Injectable HIV Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Injectable HIV Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Injectable HIV Treatment market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Injectable HIV Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Injectable HIV Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Injectable HIV Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global Injectable HIV Treatment market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Injectable HIV Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Injectable HIV Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Injectable HIV Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Injectable HIV Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Injectable HIV Treatment include Theratechnologies, ViiV Healthcare, Gilead Sciences and Janssen Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Injectable HIV Treatment, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Injectable HIV Treatment, also provides the sales of main regions and countries. Of the upcoming market potential for Injectable HIV Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Injectable HIV Treatment sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Injectable HIV Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Injectable HIV Treatment sales, projected growth trends, production technology, application and end-user industry.
Injectable HIV Treatment Segment by Company
Theratechnologies
ViiV Healthcare
Gilead Sciences
Janssen Pharmaceuticals
Injectable HIV Treatment Segment by Type
Cabotegravir
Lenacapavir
Rilpivirine
Ibalizumab
Other
Injectable HIV Treatment Segment by Application
Pre-Exposure Prophylaxis
HIV Treatment
Injectable HIV Treatment Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Injectable HIV Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Injectable HIV Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Injectable HIV Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Injectable HIV Treatment market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Injectable HIV Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Injectable HIV Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Injectable HIV Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
171 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Injectable HIV Treatment Market Size, 2020 VS 2024 VS 2031
- 1.3 Global Injectable HIV Treatment Market Size Estimates and Forecasts (2020-2031)
- 1.4 Global Injectable HIV Treatment Sales Estimates and Forecasts (2020-2031)
- 1.5 Global Injectable HIV Treatment Market Average Price (2020-2031)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 2 Global Injectable HIV Treatment Market Dynamics
- 2.1 Injectable HIV Treatment Industry Trends
- 2.2 Injectable HIV Treatment Industry Drivers
- 2.3 Injectable HIV Treatment Industry Opportunities and Challenges
- 2.4 Injectable HIV Treatment Industry Restraints
- 3 Injectable HIV Treatment Market by Manufacturers
- 3.1 Global Injectable HIV Treatment Revenue by Manufacturers (2020-2025)
- 3.2 Global Injectable HIV Treatment Sales by Manufacturers (2020-2025)
- 3.3 Global Injectable HIV Treatment Average Sales Price by Manufacturers (2020-2025)
- 3.4 Global Injectable HIV Treatment Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
- 3.5 Global Injectable HIV Treatment Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Injectable HIV Treatment Manufacturers, Product Type & Application
- 3.7 Global Injectable HIV Treatment Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Injectable HIV Treatment Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Injectable HIV Treatment Players Market Share by Revenue in 2024
- 3.8.3 2024 Injectable HIV Treatment Tier 1, Tier 2, and Tier 3
- 4 Injectable HIV Treatment Market by Type
- 4.1 Injectable HIV Treatment Type Introduction
- 4.1.1 Cabotegravir
- 4.1.2 Lenacapavir
- 4.1.3 Rilpivirine
- 4.1.4 Ibalizumab
- 4.1.5 Other
- 4.2 Global Injectable HIV Treatment Sales by Type
- 4.2.1 Global Injectable HIV Treatment Sales by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Injectable HIV Treatment Sales by Type (2020-2031)
- 4.2.3 Global Injectable HIV Treatment Sales Market Share by Type (2020-2031)
- 4.3 Global Injectable HIV Treatment Revenue by Type
- 4.3.1 Global Injectable HIV Treatment Revenue by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Injectable HIV Treatment Revenue by Type (2020-2031)
- 4.3.3 Global Injectable HIV Treatment Revenue Market Share by Type (2020-2031)
- 5 Injectable HIV Treatment Market by Application
- 5.1 Injectable HIV Treatment Application Introduction
- 5.1.1 Pre-Exposure Prophylaxis
- 5.1.2 HIV Treatment
- 5.2 Global Injectable HIV Treatment Sales by Application
- 5.2.1 Global Injectable HIV Treatment Sales by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Injectable HIV Treatment Sales by Application (2020-2031)
- 5.2.3 Global Injectable HIV Treatment Sales Market Share by Application (2020-2031)
- 5.3 Global Injectable HIV Treatment Revenue by Application
- 5.3.1 Global Injectable HIV Treatment Revenue by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Injectable HIV Treatment Revenue by Application (2020-2031)
- 5.3.3 Global Injectable HIV Treatment Revenue Market Share by Application (2020-2031)
- 6 Global Injectable HIV Treatment Sales by Region
- 6.1 Global Injectable HIV Treatment Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Injectable HIV Treatment Sales by Region (2020-2031)
- 6.2.1 Global Injectable HIV Treatment Sales by Region (2020-2025)
- 6.2.2 Global Injectable HIV Treatment Sales Forecasted by Region (2025-2030)
- 6.3 North America
- 6.3.1 North America Injectable HIV Treatment Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.3.2 North America Injectable HIV Treatment Sales by Country (2020-2031)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Injectable HIV Treatment Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.4.2 Europe Injectable HIV Treatment Sales by Country (2020-2031)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Injectable HIV Treatment Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.5.2 Asia Pacific Injectable HIV Treatment Sales by Country (2020-2031)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Injectable HIV Treatment Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.6.2 South America, Middle East and Africa Injectable HIV Treatment Sales by Country (2020-2031)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
- 7 Global Injectable HIV Treatment Revenue by Region
- 7.1 Global Injectable HIV Treatment Revenue by Region
- 7.1.1 Global Injectable HIV Treatment Revenue by Region: 2020 VS 2024 VS 2031
- 7.1.2 Global Injectable HIV Treatment Revenue by Region (2020-2025)
- 7.1.3 Global Injectable HIV Treatment Revenue by Region (2026-2031)
- 7.1.4 Global Injectable HIV Treatment Revenue Market Share by Region (2020-2031)
- 7.2 North America
- 7.2.1 North America Injectable HIV Treatment Revenue (2020-2031)
- 7.2.2 North America Injectable HIV Treatment Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.3 Europe
- 7.3.1 Europe Injectable HIV Treatment Revenue (2020-2031)
- 7.3.2 Europe Injectable HIV Treatment Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Injectable HIV Treatment Revenue (2020-2031)
- 7.4.2 Asia-Pacific Injectable HIV Treatment Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Injectable HIV Treatment Revenue (2020-2031)
- 7.5.2 South America, Middle East and Africa Injectable HIV Treatment Revenue Share by Country: 2020 VS 2024 VS 2031
- 8 Company Profiles
- 8.1 Theratechnologies
- 8.1.1 Theratechnologies Comapny Information
- 8.1.2 Theratechnologies Business Overview
- 8.1.3 Theratechnologies Injectable HIV Treatment Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.1.4 Theratechnologies Injectable HIV Treatment Product Portfolio
- 8.1.5 Theratechnologies Recent Developments
- 8.2 ViiV Healthcare
- 8.2.1 ViiV Healthcare Comapny Information
- 8.2.2 ViiV Healthcare Business Overview
- 8.2.3 ViiV Healthcare Injectable HIV Treatment Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.2.4 ViiV Healthcare Injectable HIV Treatment Product Portfolio
- 8.2.5 ViiV Healthcare Recent Developments
- 8.3 Gilead Sciences
- 8.3.1 Gilead Sciences Comapny Information
- 8.3.2 Gilead Sciences Business Overview
- 8.3.3 Gilead Sciences Injectable HIV Treatment Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.3.4 Gilead Sciences Injectable HIV Treatment Product Portfolio
- 8.3.5 Gilead Sciences Recent Developments
- 8.4 Janssen Pharmaceuticals
- 8.4.1 Janssen Pharmaceuticals Comapny Information
- 8.4.2 Janssen Pharmaceuticals Business Overview
- 8.4.3 Janssen Pharmaceuticals Injectable HIV Treatment Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.4.4 Janssen Pharmaceuticals Injectable HIV Treatment Product Portfolio
- 8.4.5 Janssen Pharmaceuticals Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Injectable HIV Treatment Value Chain Analysis
- 9.1.1 Injectable HIV Treatment Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Injectable HIV Treatment Production Mode & Process
- 9.2 Injectable HIV Treatment Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Injectable HIV Treatment Distributors
- 9.2.3 Injectable HIV Treatment Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.